title: Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention.
authors.affiliation: Department of Experimental, Diagnostic, and Specialty Medicine, Universita degli Studi di Bologna Azienda Ospedaliera Sant'Orsola-Malpighi, Bologna, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Brandi
authors.affiliation: Department of Experimental, Diagnostic, and Specialty Medicine, Universita degli Studi di Bologna Azienda Ospedaliera Sant'Orsola-Malpighi, Bologna, Italy.
authors.forename: Stefania
authors.initials: S
authors.lastname: De Lorenzo
authors.affiliation: Department of Experimental, Diagnostic, and Specialty Medicine, Universita degli Studi di Bologna Azienda Ospedaliera Sant'Orsola-Malpighi, Bologna, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Palloni
authors.affiliation: Department of Experimental, Diagnostic, and Specialty Medicine, Universita degli Studi di Bologna Azienda Ospedaliera Sant'Orsola-Malpighi, Bologna, Italy.
authors.forename: Guido
authors.initials: G
authors.lastname: Biasco
authors.affiliation: Department of Experimental, Diagnostic, and Specialty Medicine, Universita degli Studi di Bologna Azienda Ospedaliera Sant'Orsola-Malpighi, Bologna, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Tovoli
mesh_terms: D001241:Aspirin; D001650:Bile Duct Neoplasms; D001653:Bile Ducts, Intrahepatic; D002318:Cardiovascular Diseases; D018281:Cholangiocarcinoma; D006801:Humans; D010975:Platelet Aggregation Inhibitors; D012307:Risk Factors
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin